ACE 1831
Alternative Names: ACC-gamma delta T cell therapy; ACC-γδ T cell therapy; ACE-1831Latest Information Update: 15 May 2024
At a glance
- Originator Acepodia
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I Non-Hodgkin's lymphoma
Most Recent Events
- 08 May 2024 Efficacy and adverse events data from a phase I trial in Non-Hodgkin's lymphoma released by Acepodia
- 31 Jan 2023 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (Parenteral) (NCT05653271)
- 21 Jan 2023 Phase-I clinical trials in Non-Hodgkin's lymphoma (Monotherapy, Second-line therapy or greater) in Taiwan (Parenteral) (NCT05653271)